TipRanks
Advertisement
Advertisement

JP:190A Stock Latest News

Chordia Therapeutics Secures AMED Grant to Accelerate Global Development of Rogocekib
Company AnnouncementsChordia Therapeutics Secures AMED Grant to Accelerate Global Development of Rogocekib
14d ago
190A
Chordia Therapeutics Completes Initial Expansion Cohort Enrollment for Rogocekib Trial
PremiumCompany Announcements
Chordia Therapeutics Completes Initial Expansion Cohort Enrollment for Rogocekib Trial
19d ago
190A
Chordia Wins Japan Orphan Drug Status for Lead AML Therapy rogocekib
PremiumCompany Announcements
Chordia Wins Japan Orphan Drug Status for Lead AML Therapy rogocekib
2M ago
190A
Chordia’s Lead Cancer Drug Rogocekib Wins Japan Orphan Drug Endorsement for AML
PremiumCompany Announcements
Chordia’s Lead Cancer Drug Rogocekib Wins Japan Orphan Drug Endorsement for AML
3M ago
190A
Chordia Therapeutics Wins AMED Grant for Advanced Cancer Research with Kyoto University
PremiumCompany Announcements
Chordia Therapeutics Wins AMED Grant for Advanced Cancer Research with Kyoto University
3M ago
190A
Chordia Therapeutics Narrows Nine-Month Loss But Stays Deep in Red
PremiumCompany AnnouncementsChordia Therapeutics Narrows Nine-Month Loss But Stays Deep in Red
3M ago
190A
Chordia Therapeutics Sets Agenda for Q2 FY 2026 Financial and Pipeline Update
Premium
Company Announcements
Chordia Therapeutics Sets Agenda for Q2 FY 2026 Financial and Pipeline Update
6M ago
190A
Chordia Therapeutics Narrows Interim Loss but Maintains Full-Year Red-Ink Forecast
Premium
Company Announcements
Chordia Therapeutics Narrows Interim Loss but Maintains Full-Year Red-Ink Forecast
6M ago
190A
Chordia Therapeutics Doses First Patient in Rogocekib Expansion Cohort
PremiumCompany Announcements
Chordia Therapeutics Doses First Patient in Rogocekib Expansion Cohort
7M ago
190A
Chordia Advances Rogocekib Leukemia Trial With FDA-Aligned Expansion Cohorts
PremiumCompany Announcements
Chordia Advances Rogocekib Leukemia Trial With FDA-Aligned Expansion Cohorts
8M ago
190A
Chordia Regains Full Rights to CTX-177 After Ending Ono License Deal
PremiumCompany Announcements
Chordia Regains Full Rights to CTX-177 After Ending Ono License Deal
8M ago
190A
Chordia Therapeutics’ Major Shareholder Diluted Below 10% After Warrant Exercises
PremiumCompany Announcements
Chordia Therapeutics’ Major Shareholder Diluted Below 10% After Warrant Exercises
8M ago
190A
Chordia Therapeutics Narrows Quarterly Loss but Forecasts Continued Full-Year Red Ink
PremiumCompany AnnouncementsChordia Therapeutics Narrows Quarterly Loss but Forecasts Continued Full-Year Red Ink
9M ago
190A
Chordia Therapeutics to Record Grant Income in Fiscal Year 2026
Premium
Company Announcements
Chordia Therapeutics to Record Grant Income in Fiscal Year 2026
11M ago
190A
Chordia Therapeutics’ CTX-712 Study: A Potential Breakthrough in AML and HR-MDS Treatment
Premium
Company Announcements
Chordia Therapeutics’ CTX-712 Study: A Potential Breakthrough in AML and HR-MDS Treatment
12M ago
190A
Chordia Therapeutics Restructures Capital to Strengthen Financial Foundation
PremiumCompany Announcements
Chordia Therapeutics Restructures Capital to Strengthen Financial Foundation
12M ago
190A
Chordia Therapeutics Reports Fiscal Year 2025 Financial Results
PremiumCompany Announcements
Chordia Therapeutics Reports Fiscal Year 2025 Financial Results
12M ago
190A
Chordia Therapeutics Reports Continued Losses in Latest Financial Results
PremiumCompany Announcements
Chordia Therapeutics Reports Continued Losses in Latest Financial Results
1y ago
190A
Chordia Therapeutics Secures Grant for Cancer Therapy Research
PremiumCompany Announcements
Chordia Therapeutics Secures Grant for Cancer Therapy Research
1y ago
190A
Chordia Therapeutics Announces Change in Major Shareholder
PremiumCompany AnnouncementsChordia Therapeutics Announces Change in Major Shareholder
1y ago
190A
Chordia Therapeutics Regains Rights to CTX-177 as Ono Discontinues Development
Premium
Company Announcements
Chordia Therapeutics Regains Rights to CTX-177 as Ono Discontinues Development
1y ago
190A
Chordia Therapeutics Reports Financial Losses for Six-Month Period Ending February 2025
Premium
Company Announcements
Chordia Therapeutics Reports Financial Losses for Six-Month Period Ending February 2025
2y ago
190A

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >